42.26MMarket Cap-65116P/E (TTM)
2.930High2.650Low291.95KVolume2.650Open2.750Pre Close831.97KTurnover9.44%Turnover RatioLossP/E (Static)15.09MShares4.20052wk High7.04P/B8.66MFloat Cap0.40052wk Low--Dividend TTM3.09MShs Float5.900Historical High--Div YieldTTM10.18%Amplitude0.400Historical Low2.849Avg Price1Lot Size
Wang & Lee Group Stock Forum
1. ATR-12: This is being developed to treat Netherton syndrome, a rare skin condition with no current FDA-approved treatment. Initial safety data from a 12-patient trial is expected by late 2024, which will mark a crucial step in its clinical progression.
2. ATR-04: Targeting skin rashes associated with EGFR inhibitors (commonly used in cancer therapies), the IND submission is planned for mid-2024. The first-in-hum...
No comment yet